Medical technology titan chooses Kneat for its services
Kneat Expands Footprint in Global Medical Technology Sector
Kneat.com, a leading provider of digital validation solutions, has signed a three-year Master Services Agreement with an unnamed global medical technology company. This agreement marks a significant step in Kneat's expansion strategy, which is centred around a "land and expand" approach.
The strategy involves initially securing a footprint within a client's ecosystem and then scaling across various sites and multiple use cases of validation processes to deepen engagement and drive broader adoption. Kneat aims to have each customer progressively increase usage of its digital validation and quality process automation platform across different locations and applications.
This approach supports sustainable growth and helps the company leverage existing relationships for continued expansion within its highly regulated life sciences and medical technology markets. In Q2 2025, Kneat announced a 32% year-over-year revenue increase with a 43% increase in annual recurring revenue, underpinned by new customer wins and a robust pipeline.
The global medical technology company's scaling of Kneat's software within its organization is contingent upon various factors. The company, a division of a larger manufacturer headquartered in Asia, employs over 30,000 people and operates in more than 160 countries worldwide. The future use and implementation timeline of Kneat's software within the global medical technology company's validation processes is uncertain.
Kneat's software platform, Kneat Gx, is designed to deliver incremental value and benefits in the years to come. It is fully ISO 9001 and ISO 27001 certified, fully validated, and 21 CFR Part 11/Annex 11 compliant. Investors should be aware that continued reliance on forward-looking statements is at their own risk. Kneat does not guarantee the accuracy of any forward-looking statements and does not undertake to update them unless required by securities laws.
For more information about Kneat, visit www.kneat.com. Kneat Investor Relations can be contacted for further information at +1 905-251-2929 or [email protected]. Eddie Ryan, Kneat CEO, stated that the new signing underscores the confidence in Kneat within the life sciences sector.
However, it's important to note that the Master Services Agreement between Kneat.com, Inc. and the global medical technology company is subject to potential changes and uncertainties. The compliance of Kneat's platform under regulatory audit and inspection is also subject to potential variations.
[1] Source: Kneat.com Investor Presentation, Q2 2025 [3] Source: Kneat.com Press Release, Kneat Gx 9.5 Launch, 2025 [4] Source: Kneat.com Press Release, Q2 2025 Financial Results, 2025
- Kneat.com's digital validation solutions, like the AI-powered Kneat Gx platform, are designed to expand within the global medical technology sector, aligning with the company's "land and expand" strategy.
- As Kneat's software is deployed and scaled across multiple sites and use cases within a client's ecosystem, it aims to drive broader adoption and foster sustainable growth in the tech-driven life sciences and medical technology markets.
- The tech industry, encompassing digital devices and data management, plays a crucial role in health-and-wellness and medical-conditions, as demonstrated by the increasing reliance on technology in the life sciences sector.
- The global medical technology company, a division of a large Asian conglomerate, has the potential to enhance its validation processes through the integration of Kneat's software, which is fully ISO 9001 and ISO 27001 certified, and compliant with regulatory standards like 21 CFR Part 11/Annex 11.
- Science and technology have the capacity to revolutionize the medical industry, as shown by Kneat's software platform, which delivers incremental value and benefits, improving the efficiency and accuracy of validation processes.
- Despite the promising Master Services Agreement and the growth Kneat has demonstrated, it's essential to acknowledge the potential changes, uncertainties, and variations that may arise during regulatory audits and inspections within the highly-regulated life sciences and medical technology sectors.
